

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Kazmierski et al.  
International App. No.: PCT/US2003/039644  
International Filing Date: December 12, 2003  
Title: *CCR5 Antagonists as Therapeutic Agents*

---

**COMMISSIONER FOR PATENTS**  
**P.O. Box 1450**  
**Alexandria, VA 22313-1450**

**PRELIMINARY AMENDMENT**

Sir:

The above-identified application is being transmitted herewith for entry in the United States National Phase under Chapter II of the PCT for the purposes of adding priority information.

Prior to examination on the merits, please amend the application as follows:

Amendments to the Specification are reflected on page 3.


Amendments to the Claims are reflected in the listing of claims which begin on page 4.

Remarks/Arguments begin on page 48.

The **Abstract** appears after page 48 of this paper.

Express Mail Label No.: EV332065690US  
Date of Mailing: 6/9/05

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to "Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on the date shown above.

  
Patty Wilson